Idelalisib has CLL on the run!

被引：4
作者：
Brown, Jennifer R. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2015年 / 126卷 / 25期
关键词：
TREATMENT-NAIVE;
D O I：
10.1182/blood-2015-10-676890
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, O'Brien et al report mature results of initial treatment of chronic lymphocytic leukemia (CLL) with the PI3K delta inhibitor idelalisib plus rituximab, and demonstrate that the combination is extremely effective with manageable toxicity in an older patient population.(1)
引用
收藏
页码：2656 / 2657
页数：4
相关论文
共 10 条
  • [1] [Anonymous], LEUK LYMPHOMA
  • [2] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven E.
    Burger, Jan A.
    Blum, Kristie A.
    Coleman, Morton
    Wierda, William G.
    Jones, Jeffrey A.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Shaw, Yun
    Bilotti, Elizabeth
    Zhou, Cathy
    James, Danelle F.
    O'Brien, Susan
    [J]. BLOOD, 2015, 125 (16) : 2497 - 2506
  • [3] Coutre S, 2015, ASCO M ABSTRACTS S, V33
  • [4] Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
    Goede, V.
    Fischer, K.
    Engelke, A.
    Schlag, R.
    Lepretre, S.
    Montero, L. F. C.
    Montillo, M.
    Fegan, C.
    Asikanius, E.
    Humphrey, K.
    Fingerle-Rowson, G.
    Hallek, M.
    [J]. LEUKEMIA, 2015, 29 (07) : 1602 - 1604
  • [5] Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides
    Louie, Christine Y.
    DiMaio, Michael A.
    Matsukuma, Karen E.
    Coutre, Steven E.
    Berry, Gerald J.
    Longacre, Teri A.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (12) : 1653 - 1660
  • [6] A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
    O'Brien, Susan M.
    Lamanna, Nicole
    Kipps, Thomas J.
    Flinn, Ian
    Zelenetz, Andrew D.
    Burger, Jan A.
    Keating, Michael
    Mitra, Siddhartha
    Holes, Leanne
    Yu, Albert S.
    Johnson, David M.
    Miller, Langdon L.
    Kim, Yeonhee
    Dansey, Roger D.
    Dubowy, Ronald L.
    Coutre, Steven E.
    [J]. BLOOD, 2015, 126 (25) : 2686 - 2694
  • [7] Cutting edge:: The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells
    Patton, Daniel T.
    Garden, Oliver A.
    Pearce, Wayne P.
    Clough, Louise E.
    Monk, Clare R.
    Leung, Eva
    Rowan, Wendy C.
    Sancho, Sara
    Walker, Lucy S. K.
    Vanhaesebroeck, Bart
    Okkenhaug, Klaus
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (10) : 6598 - 6602
  • [8] FOXP3 and scurfy: how it all began
    Ramsdell, Fred
    Ziegler, Steven F.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2014, 14 (05) : 343 - 349
  • [9] Sharman JP, 2014, BLOOD, V124
  • [10] Idelalisib-associated Colitis Histologic Findings in 14 Patients
    Weidner, Anna-Sophie
    Panarelli, Nicole C.
    Geyer, Julia T.
    Bhavsar, Erica B.
    Furman, Richard R.
    Leonard, John P.
    Jessurun, Jose
    Yantiss, Rhonda K.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (12) : 1661 - 1667
1